Bringing all the omics together

Dr. Szilard Voros, CEO of Global Genomics Group (G3), shares how he and his team of researchers embarked on an ambitious journey to transform drug discovery using big data. With 48 participating clinical sites, three continents, nine countries, and nearly 8,000 patients, the study is the largest clinical trial to date that has used a multiomics approach to look at trends in disease states.


A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

*Data calculations on file. Illumina, Inc., 2015.

View customer spotlight videos

View Illumina webinars

View Illumina product videos

View Illumina support videos